About Metagenomi
Metagenomi is a company based in Berkeley (United States) founded in 2016 by Brian Thomas. Metagenomi has raised $376.37 million across 6 funding rounds from investors including Moderna, Bayer and Marshall Wace. The company has 202 employees as of December 31, 2024. Metagenomi operates in a competitive market with competitors including Beam Therapeutics, DNAnexus, eGenesis, Cytel and Korro Bio, among others.
- Headquarter Berkeley, United States
- Employees 202 as on 31 Dec, 2024
- Founders Brian Thomas
- Stage Public
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Metagenomi, Inc.
-
Annual Revenue
$52.3 M (USD)16.84as on Dec 31, 2024
-
Net Profit
-$78.06 M (USD)-14.36as on Dec 31, 2024
-
EBITDA
-$83.49 M (USD)-12.4as on Dec 31, 2024
-
Total Equity Funding
$376.37 M (USD)
in 6 rounds
-
Latest Funding Round
$100 M (USD), Series B
Dec 20, 2022
-
Investors
Moderna
& 21 more
-
Employee Count
202
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Metagenomi
Metagenomi is a publicly listed company on the NASDAQ with ticker symbol MGX in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Metagenomi
Unlock access to complete
Unlock access to complete
Funding Insights of Metagenomi
Metagenomi has successfully raised a total of $376.37M across 6 strategic funding rounds. The most recent funding activity was a Series B round of $100 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Metagenomi
Metagenomi has secured backing from 22 investors, including venture fund and institutional investors. Prominent investors backing the company include Moderna, Bayer and Marshall Wace.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private equity and venture capital fund focused on the healthcare sector
|
Locked | Locked | Locked | |
|
Venture capital is provided to biomedical technology startups.
|
Locked | Locked | Locked | |
|
Investments in healthcare companies are made by SymBiosis.
|
Locked | Locked | Locked |
Investor details for Metagenomi
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Metagenomi
Investment portfolio details for Metagenomi
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Metagenomi
Detailed financials for Metagenomi
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Metagenomi Comparisons
Peer comparison for Metagenomi
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Metagenomi
Metagenomi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beam Therapeutics, DNAnexus, eGenesis, Cytel and Korro Bio, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of gene therapy using CRISPR base editing to treat diseases
|
|
| Locked | Locked | Locked |
Cloud-based genome informatics and data management are provided.
|
|
| Locked | Locked | Locked |
Gene transplantation platform for humanizing pig cells is developed.
|
|
| Locked | Locked | Locked |
Data analysis and statistical solutions are provided for life sciences.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Metagenomi
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Metagenomi
Complete news archive for Metagenomi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Metagenomi
Metagenomi was founded in 2016 and raised its 1st funding round 3 years after it was founded.
Metagenomi is headquartered in Berkeley, United States. It is registered at Berkeley, California, United States.
Brian Thomas is the current CEO of Metagenomi. They have also founded this company.
Metagenomi is a funded company, having raised a total of $376.37M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Metagenomi is 202.
Annual revenue of Metagenomi is $52.3M as on Dec 31, 2024.
Metagenomi was founded in 2016 and is based in Berkeley, United States. Digital gene editing technologies are advanced by the company within the biotechnology sector for drug development purposes. A next-generation tool has been engineered to support drug enhancement and design. Operations center on creating editing solutions for therapeutic applications, with a focus on precision in genetic modifications.
Metagenomi's top competitors include DNAnexus, eGenesis and Tessera Therapeutics.
Yes, Metagenomi is publicly traded on NASDAQ under the ticker symbol MGX.
Metagenomi has 22 investors. Key investors include Moderna, Bayer, Marshall Wace, Citadel, and RA Capital.
The ticker symbol of Metagenomi is MGX on NASDAQ.